Spectrum Expands Fusilev Manufacturing
Spectrum announced that the FDA has approved an additional manufacturing facility for the production of Fusilev (levoleucovorin) for injection. Spectrum has continued to increase the number of qualified third-party manufacturing sites approved for Fusilev production since its approval to ensure long-term supply.
Fusilev, a folate analogue, was recently approved for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. Fusilev is also indicated for rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.
For more information call (877) FUSILEV or visit www.fusilev.com.